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Abstract
Aim: The Scale of Prodromal Symp-
toms (SOPS) was developed to iden-
tify individuals experiencing early
signs of psychosis, a critical first step
towards early intervention. Prelimi-
nary dimension reduction analyses
suggested that psychosis-risk symp-
tomsmay deviate from the traditional
symptom structure of schizophrenia,
but findings have been inconsistent.
This study investigated the phenom-
enology of psychosis risk symptoms
in a large sample from a multi-site,
national study using rigorous factor
analysis procedure.
Methods: Participants were 334 help-
seeking youth (age: 17.0 ± 3.3) from
the Early Detection and Intervention
for the Prevention of Psychosis
Program, consisting of 203 partici-
pants at clinically higher risk (sum of
P scores ≥ 7), 87 with clinically lower
risk (sum of P scores < 7) and 44 in
very early first-episode psychosis (<30
days of positive symptoms). Baseline
SOPS data were subjected to principal
axis factoring (PAF), estimating
factors based on shared variance,
with Oblimin rotation.
Results: PAF yielded four latent
factors explaining 36.1% of total vari-
ance: positive symptoms; distress;
negative symptoms; and deteriorated
thought process. They showed rea-
sonable internal consistency and
good convergence validity, and were
not orthogonal.
Conclusions: The empirical factors of
the SOPS showed similarities and
notable differences compared with
the existing SOPS structure. Regroup-
ing the symptoms based on the
empirical symptom dimensions may
improve the diagnostic validity of the
SOPS. Relative prominence of the
factors and symptom frequency
support early identification strategies
focusing on positive symptoms and
distress. Future investigation of long-
term functional implications of these
symptom factors may further inform
intervention strategies.
Key words: factor analysis, prodrome, psychosis, schizophrenia, ultra
high risk.
INTRODUCTION
Schizophrenia is a severe and chronic mental disor-
der that often requires long-term treatment and
care. Data accumulated over the past decades have
shown that duration of untreated psychosis is a reli-
able predictor of poor prognosis and long-term
outcome,1–4 providing a strong argument for early
intervention. Treatment of psychosis at first episode
or early on during the course has shown promising
results, including reduced relapse rate and better
psychosocial functioning.5 More recently, it has
been shown that prolonged untreated illness,
including the symptomatic period just before the
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onset of frank psychosis (i.e. the prodrome), also
significantly predicts poorer outcome,6 calling for
efforts to identify and deliver treatment even earlier
in order to prevent schizophrenia and improve
outcome.7
A critical first step towards early identification
and intervention is the development of a reliable
and valid assessment tool. The Structured Interview
for Prodromal Syndrome (SIPS) was one of several
instruments developed to diagnose those at a high
risk of developing psychosis.8–10 It was renamed as
Structured Interview for Psychosis-Risk Syndromes
in 200911 to better reflect its function of prospec-
tively identifying at-risk individuals (i.e. those dis-
playing subtle psychotic-like symptomswhomay or
may not eventually develop psychosis). The North
American Prodrome Longitudinal Study used the
SIPS in a cohort of 291 individuals, finding a pro-
spective conversion rate of 35% at 21⁄2 years, sup-
porting the predictive validity of the SIPS.12
However, the modest positive predictive value of a
psychosis risk syndrome diagnosis by the SIPS,
along with other controversies on the diagnostic
reliability in clinical practice, potential overuse of
antipsychotics and stigma, led to heavy debates on
the appropriateness of including psychosis risk syn-
drome as a diagnostic category in the Diagnostic
and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-V).13 In the end, ‘attenuated psychosis
syndrome’ was adopted and included in Section III
of the DSM-V as a condition for further study.14 Dis-
tinguished from psychosis risk syndrome (which
primarily emphasizes the risk of developing full-
blown psychosis), attenuated psychosis syndrome
is ‘a currently relevant clinical condition leading to
help seeking, with many more clinical outcomes
other than conversion to psychosis.’14 The idea
builds upon a common observation in clinical high-
risk studies that although the majority of these indi-
viduals do not eventually develop psychosis, many
of them otherwise present significant clinical symp-
toms, distress and/or functional impairment that
fulfill DSM’s general criteria for mental disorders
and should receive clinical care.15,16
This shift, from preventing psychosis conversion
to addressing the diverse clinical needs of at-risk
individuals to improve outcome, necessitates a
better understanding of the phenomenology of the
clinical high-risk state. The current structure of the
Scale of Prodromal Symptoms (SOPS),11,17 a major
diagnostic component of the SIPS, implies that the
symptom structure of psychosis risk is similar to
that of schizophrenia. Specifically, the SOPS con-
sists of 19 items divided into four subscales – posi-
tive symptoms (P; five items), negative symptoms
(N; six items), disorganization symptoms (D; four
items), and general symptoms (G; four items) – with
only the positive symptoms being considered diag-
nostic of psychosis risk. The empirical support for
this symptom structure is unclear. Thus far, we are
aware of only three studies published in English that
examined the factor structure of the SOPS,18–20 and
the results varied remarkably. Hawkins et al.18
reported a three-component (negative/general/
positive symptoms) and a two-component
(positive/negative symptoms) solution. Klaassen
et al.19 reported a four-component solution similar
to the four dimensions inherent to the SOPS, though
with four items failing to load satisfactorily on any
components. Comparelli et al.20 reported a three-
component solution (negative/general/positive
symptoms), but the constituent items of the three
components were remarkably different from those
reported by Hawkins et al.18
One source of these inconsistent results may be
sample sizes. For principal component analysis
(PCA), the dimension reduction method used in
these three studies, a general rule of thumb is a
sample size of at least 300,21 or a subject-to-item
ratio of at least 10:1.22 This means at least 190 sub-
jects are required given the 19 SOPS items. The
sample sizes of these three studies were only
between 77 and 128. Inadequate sample size and
subject-to-item ratio are known to cause over-fitting
of data, resulting in unstable factor loadings,
unreplicable factors, and lack of generalizability to
the population.23 Thus, a larger sample is needed to
reveal the factor structure of psychosis risk that is
more stable and generalizable to the population.
Another limitation of previous studies is their use
of PCA and varimax (orthogonal) rotation. Although
PCA is a useful dimension reduction method, it is
not truly a factor analysis. PCA is an extraction
method that uses all variance, including random
errors unique to individual items, thus producing
inflated total variance explained and factor loadings
compared with exploratory factor analysis that uses
only shared variance to estimate latent factors.
Further, since some of the symptom dimensions
(e.g. positive symptoms and distress) are likely to be
correlated rather than completely orthogonal,
oblique rotation would be more appropriate than
varimax rotation because it allows factors to corre-
late, and it will produce nearly identical solutions if
the factors are truly orthogonal.24
With the above considerations in mind, we inves-
tigated the phenomenology of psychosis risk by
examining the factor structure of the SOPS using
principal axis factoring (PAF) with Oblimin rotation,
based on a large sample from the Early Detection
SOPS factor analysis
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and Intervention for the Prevention of Psychosis
Program (EDIPPP).
METHODS
Participants
The participants of this study were enrolled in the
EDIPPP, a national research programme modelled
after the Portland (Maine) Identification and Early
Referral (PIER) program.25 EDIPPP included six par-
ticipating sites: (i) PIER, Portland, ME; (ii) Recogni-
tion andPrevention (RAP) Program,Queens,NY; (iii)
Michigan Prevents Prodromal Progression (M3P)
Program, Ann Arbor, MI; (iv) Early Assessment and
Support Team (EAST) Program, Salem, OR; (v) Early
Diagnosis andPreventiveTreatment (EDAPT)Clinic,
Sacramento, CA; and (vi) Early Assessment and
Resource Linkage for Youth (EARLY), Albuquerque,
NM. The programme included a research protocol
that consisted of clinical and neuropsychological
assessments as well as clinical interventions includ-
ing psychopharmacology, psychoeducationalmulti-
family group therapy and supported education/
employment interventions.26,27
Participants of EDIPPP were help-seeking youth
aged 12–25 years and having at least a ‘1’ on any of
the positive symptoms or a ‘3’ on any of the negative
symptoms of the SOPS. Participants with a current
psychotic episode > 30 days, a prior psychotic
episode, prior antipsychotic treatment > 30 days,
psychotic symptoms due to an acute medical or
toxic aetiology, or an IQ < 70 were excluded. More
details on identification methods and inclusion/
exclusion criteria can be found in McFarlane et al.28
Participants and their families attended a
research orientation and preliminary screening
session in which they were provided with informa-
tion about the research protocol and informed
consent was obtained from participants (and their
parents/guardians if under age 18). Comprehensive
clinical and neuropsychological research assess-
ments were conducted at baseline andmultiple lon-
gitudinal follow-ups, but only the baseline data are
reported in this paper.
A total of 520 participants were enrolled between
September 2007 and June 2010, out of which 337
met the inclusion criteria. Based on a risk-based
allocation study design, qualified participants were
then classified, according to their SOPS scores, as
clinically lower risk (CLR; sum of P scores < 7), clini-
cally higher risk (CHR; sum of P scores ≥ 7), and
early first-episode psychosis (EFEP; at least one P
symptom rated 6, and all P symptoms rated 6
lasted < 30 days).20 EFEP consisted of subjects who
met criteria for the Presence of Psychotic Symp-
toms, modified to include subjects with less than 1
month of psychotic symptoms, but with greater
duration and frequency than seen for Brief Intermit-
tent Psychotic Syndrome. This sample was included
because EDIPPP aimed at improving role and social
functional outcomes in addition to the traditional
emphasis of delaying/preventing psychosis.25,28,29
SCID-derived diagnoses30 showed that 84% of this
sample met criteria for one or more current or life-
time Axis-I diagnoses, including major depressive
disorder (42%), anxiety disorder (36%), psychosis
(current only; 13%), substance abuse (8%) and other
(5%; see for detail28). Three participants did not have
complete SOPS scores and were excluded from the
analysis. Characteristics of the remaining 334 par-
ticipants are summarized in Table 1.
Assessments
The baseline assessment of EDIPPP included a
developmental and treatment history interview,
clinical research interviews, cognitive testing, family
history interviews, a substance use survey, and
current functioning assessments. For the purpose of
this report, only data of the SOPS, the Positive and
Negative Syndrome Scales (PANSS)31 and the Global
Functioning Scales32 were used in the analyses. All
assessments were administered by trained and
independent research interviewers. Inter-rater reli-
ability for SOPS is summarized in Table 2.
Statistical analyses
Baseline data on the SOPS from the entire EDIPPP
sample were subjected to PAF with Oblimin
rotation. Solutions were obtained based on the
screeplot, residuals of reproduced correlations, and
conceptual interpretability of the factors. The deci-
sion to include CLR and EFEP in addition to CHR
participants was based on our theoretical assump-
tion that psychosis is a continuum, cutting across
normal experiences and pathology.28,33 Separate
PAFs were also performed for CHR participants only
(n = 203), CHRplus EFEP participants (n = 247), and
CHRplus CLR participants (n = 290) for comparison
purposes. However, no satisfactory solutions were
obtained using these subsamples due to suboptimal
measures of sample adequacy (many items < 0.7),
high proportion of residuals of reproduced correla-
tions > 0.05, poor factor loadings of several items,
and questionable interpretability of the extracted
factors. These quality control measures suggested
that factor analysis was inappropriate with the
subsamples, likely due to the reduced sample size
I. F. Tso et al.
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and restricted range of scores. Therefore, these
results are not included in this report.
Convergence validity of the factors yielded in the
PAF was examined by correlating with their corre-
sponding empirical factors of the PANSS based on a
large recent-onset psychosis sample34 – positive (P1,
G9, P3, P6, P5, G12, G15), anxiety and depression
(G6, G3, G1, G2, G4), negative (N4, N2, N3, G16, N6,
N1, G13) and disorganized (G10, G11, N5, P2, N7).
See Supporting Information Table S1 for item
content of the PANSS.
Finally, symptom frequency among the CHR par-
ticipants was examined. Only symptoms ratedmod-
erate or above (≥3) on the SOPS were included.
RESULTS
Item distributions
The distribution of the SOPS items of the whole
sample, as well as broken down by CLR, CHR and
EFEP, are displayed inTable 3. Overall, themean and
SD of the SOPS items of our sample showed remark-
able resemblance to those reported in Hawkins
et al.18 and Klaassen et al.19 The mean of D2 (bizarre
thinking) in our sample (1.10 ± 1.32) was lower than
that in Hawkins et al.18 (2.10 ± 1.62), t(426) = 6.12,
P < 0.001, but similar to that in Klaassen et al.19
(0.92 ± 1.49), t(409) = 1.05, P = 0.29. In addition, G2
(dysphoric mood) was higher in our sample
(3.91 ± 1.57) than in both Hawkins et al.18
(2.95 ± 1.67), t(426) = 5.16, P < 0.001, and Klaassen
et al.19 (3.06 ± 1.51), t(409) = 4.31, P < 0.001. This
may be due to the high prevalence of mood disor-
ders in our sample, but direct comparisons were
infeasible because these two studies did not report
the scores or rate of depression.
Factor structure of SOPS
PAF yielded a four-factor solution with the most
acceptability based on fit statistics and conceptual
interpretability of the factors. Since item G3 (motor
disturbances) had loadings <0.30 on all of the
factors, it was removed from the analysis. PAF was
re-performed and, again, a four-factor solution
was yielded, explaining 36.1% of total variance
(Table 4a). The factors were labelled as: (1) posi-
tive symptoms (P1, P2, P3, P4, D2; variance
explained = 18.7%); distress (G1, G2, G4; variance
TABLE 1. Participant characteristics
Clinical lower-risk
(n = 87)
Clinical higher-risk
(n = 203)
Early first-episode
psychosis (n = 44)
All (N = 334)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age 16.7 ± 3.2 16.8 ± 3.3 18.4 ± 3.2 17.0 ± 3.3
Sex (male/female) 61/26 115/88 26/18 202/132
Race†
African American 5 (5.7%) 16 (7.9%) 10 (22.7%) 31 (9.3%)
Asian American 4 (4.6%) 9 (4.4%) – 13 (3.9%)
Caucasian 62 (71.3%) 124 (61.1%) 20 (45.5%) 206 (61.7%)
American Indian/Alaskan Native 2 (2.3%) 2 (1.0%) – 4 (1.2%)
Native Hawaiian or other Pacific Islander 1 (1.1%) – 1 (2.3%) 2 (0.6%)
Other 4 (4.6%) 17 (8.4%) 4 (9.1%) 25 (7.5%)
More than one race 6 (6.9%) 25 (12.3%) 7 (15.9%) 38 (11.4%)
Global functioning‡
Social 6.45 ± 1.53 6.11 ± 1.39 5.97 ± 1.49 6.18 ± 1.46
Role 5.67 ± 2.31 5.46 ± 2.32 4.35 ± 2.73 5.41 ± 2.36
†<7% missing data.
‡15 cases missing.
TABLE 2. Inter-rater reliability (intraclass correlation) of the SOPS across the six EDIPPP sites
Site
PIER (ME) RAP (NY) M3P (MI) EDAPT (CA) EAST (OR) EARLY (NM) All
Positive symptoms 0.94 0.88 0.89 0.93 0.90 0.82 0.91
Negative symptoms 0.90 0.93 0.91 0.91 0.90 0.92 0.92
SOPS factor analysis
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explained = 9.1%); negative symptoms (N1, N2,
N3, N4, D1, D4; variance explained = 5.3%); and
deteriorated thought process (P5, N5, N6, D3; vari-
ance explained = 3.0%). The four factors showed
small to medium correlations with each other (r
ranged from 0.14 to 0.32), and had fair to good inter-
nal consistency (Cronbach’s α ranged from 0.53 to
0.75; Table 4b).
Convergence validity of the four factors was sup-
ported by the finding that they showed strongest
correlations with their corresponding empirically
derived PANSS factors,34 with r ranging from 0.63 to
0.84 (Table 5).
Symptom frequency
Frequency of symptoms rated 3 or above on the
SOPS in the CHR sample was examined. The most
prevalent symptoms were mostly those loaded
on the positive symptoms factor, including P4
(perceptual abnormalities/hallucinations; n = 122),
P1 (Unusual thought content/delusional ideas;
n = 104) and P2 (suspiciousness/persecutory ideas;
n = 81). In addition, G2 (dysphoric mood; n = 109)
of the distress factor, N6 (deterioration in role func-
tioning; n = 106) of the deteriorated thought process
factor, and N2 (avolition; n = 82) of the negative
symptoms factor were also quite common.
DISCUSSION
Using a large sample from EDIPPP, we found four
latent factors (positive symptoms, distress, negative
symptoms, and deteriorated thought process)
explaining 36% of total variance in the symptoms
TABLE 4A. Rotated structure matrix of SOPS items (N = 334)
Factor
Positive
symptoms
Distress Negative
symptoms
Deteriorated
thought process
P1. Unusual thought content/delusional ideas 0.80
D2. Bizarre thinking 0.74
P2. Suspiciousness/persecutory ideas 0.60
P4. Perceptual abnormalities/hallucinations 0.51
P3. Grandiosity 0.47
G2. Dysphoric mood 0.76
G4. Impaired tolerance to normal stress 0.62
G1. Sleep disturbances 0.47
N1. Social isolation and withdrawal 0.62
N3. Decreased expression of emotion 0.61
N2. Avolition 0.51 0.48 0.39
D1. Odd behaviour or appearance 0.37 0.41
N4. Decreased experience of emotion and self 0.39 0.40
D4. Impairment in personal hygiene 0.39
P5. Conceptual disorganization 0.45 0.58
N5. Decreased ideational richness 0.46
D3. Trouble with focus and attention 0.43 0.46
N6. Deterioration in role functioning 0.37 0.32 0.41
Item G3 was removed from the analysis due to poor loading on all of the factors. Kaiser-Meyer-Olkin Measure of Sampling Adequacy = 0.78. Items with
loadings > 0.32 on more than one factor are assigned to factors that are most theoretically consistent (factor loadings bolded). Factor loadings <0.32 are
not displayed for clarity.
TABLE 4B. Factor correlation matrix
Positive
symptoms
Distress Negative
symptoms
Deteriorated
thought process
Positive symptoms (0.75)
Distress 0.16 (0.64)
Negative symptoms 0.14 0.25 (0.66)
Deteriorated thought process 0.24 0.18 0.32 (0.53)
Numbers in parentheses are Cronbach’s alpha based on items assigned to the corresponding factor.
SOPS factor analysis
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measured by the SOPS. Since the factors were esti-
mated using shared variance only (i.e. excluding
random errors unique to individual items), the % of
total variance explained is bound to be smaller com-
pared with PCA, which uses all (including measure-
ment error) variance in component extraction.
Given this, the amount of variance explained
reported in this study is quite comparable to the 55%
of total variance explainedby the five principal com-
ponents of PANSS reported in Emsley et al.34 These
four latent factors showed reasonable to good inter-
nal consistency and convergence validity, and they
were not completely orthogonal. This four-factor
solution resembles closely the four-factor structure
implied by the SOPS and the widely accepted
symptom structure of schizophrenia: positive symp-
toms (P), negative symptoms (N), disorganization
(D) and general symptoms (G). However, we noted
twomajor differences that have diagnostic and con-
ceptual implications for the SOPS and the phenom-
enologyofpsychosis risk. First, the constituent items
of the fourempirical factorsdiffer fromthosemaking
up the four subscales of the SOPS.While the positive
symptoms, distress, and negative symptoms factors
consisted of mostly items from their corresponding
SOPS subscales, they also consisted of items from
other SOPS subscales. In addition, the deteriorated
thought process factor consisted of amixture of P, G,
N andD items. Since the positive symptom subscale
of the SOPS is the only subscale considered to be
diagnostic of psychosis risk, its inclusion of an item
(P5) that failed to load onto the positive symptoms
factor and that the positive symptoms factor
included a D item suggested that reassigning some
SOPS symptoms to other subscalesmay improve the
diagnostic validity of the SIPS.
Another noted difference was the relative promi-
nence of the symptom dimensions. Consistent with
the SOPS/schizophrenia symptom structure, posi-
tive symptoms were found to be the most promi-
nent symptoms in this study, explaining 18.7% of
total variance. However, while negative symptoms
are considered a symptom dimension as important
as positive symptoms in schizophrenia, our results
showed that the distress factor (9.1%) accounted for
more variance than the negative symptoms factor
(5.3%) in this population. This was not surprising,
given that 42% of this sample had a co-morbid
major depressive disorder and 36%had a co-morbid
anxiety disorder, similar to figures previously
reported.35 Dysphoric mood, in addition to func-
tional decline and positive symptoms, was among
the most common signs in our CHR sample. Loewy
et al.36 found that assessing distress associated with
endorsed positive symptoms significantly increased
the specificity of their psychosis risk syndrome
screening tool, supporting the importance of
assessing distress in early identification. Although
baseline anxiety and depression do not seem to
predict transition to psychosis,35 they are associated
with long-term functional outcome in psychosis
risk syndrome.37 Distress may reflect a failure to
effectively regulate emotional response to psychotic
symptoms, thus adversely affecting role and social
functioning. Taken together, our findings lend
further support to early identification and interven-
tion strategies focusing on positive and distress
symptoms (see also38).
As noted above, the deteriorated thought process
factor consisted of a mixture of P, N and D items.
Examination of the content of these items reveals
that these items together tap into compromised but
rather non-specific thought and attention func-
tions. This suggests that disorganization symptoms
manifest in amilder andmore unspecificmanner in
psychosis risk comparedwith schizophrenia. Never-
theless, there is evidence that disorganized symp-
toms are highly predictive of functional outcome in
a clinical high risk sample, suggesting that subtle
disorganized symptoms warrants equal attention
and monitoring as do other symptoms in psychosis
risk.39
TABLE 5. Convergence validity of the four empirical factors of SOPS (N = 334)
PANSS† Factor 1 Factor 2 Factor 3 Factor 4
Positive
symptoms
Distress Negative
symptoms
Deteriorated
thought process
Positive 0.84 0.24 0.27 0.34
Anxiety and depression 0.41 0.63 0.26 0.22
Negative 0.17 0.31 0.73 0.32
Disorganized 0.37 0.14 0.31 0.63
Shaded cells are correlations that are expected to be strongest (relative to other cells in the same row or column) in order to support convergence validity
of the four empirical factors of SOPS.
†Empirical factors of the Positive and Negative Syndrome Scales reported in Emsley et al.34
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One potential limitation of this study was the
characteristic of the sample. It consisted of CLR and
EFEP individuals in addition to CHR, differing from
the traditional approach of treating psychosis risk as
a distinct entity.18,19 Technically, for the factor analy-
sis result to be considered reflective of the phenom-
enology of psychosis risk, it should be based on a
CHR sample. However, despite the relatively large
sample size of this study, the CHR sample was still
not large enough to produce adequate statistical fit
for valid factor analysis results. The validity of the
factor analysis in this heterogeneous sample rests
on the assumption that the latent factor structure is
continuous across the range of symptoms assessed.
Testing this assumption will require a much larger
sample from the low-risk and very early psychosis
groups. However, given the premise that pathology
is continuous with normal variation, the current
study provides a good first-pass analysis capturing a
wider range of scores in a sufficiently powered
sample. The results based on the entire EDIPPP
sample should be considered as reflecting the phe-
nomenology among help-seeking youth with sus-
pected psychosis risk or very early psychosis.
To conclude, the empirical factor structure of the
SOPS showed similarities but significant differences
comparedwith the current SOPS structure as well as
the traditional symptom structure of schizophrenia.
This suggests that regrouping the SOPS items
according to the underlying symptom dimensions
may help refine the diagnostic validity of the instru-
ment. Examination of the relative prominence of
the empirical factors of the SOPS and symptom fre-
quency supported the importance of early identifi-
cation strategies focusing on positive symptoms
and distress. Future investigation of long-term func-
tional implications of these symptom factors may
further inform intervention strategies.
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